Log in

Hutchison China MediTech Share Forecast, Price & News

GBX 476
-10.00 (-2.06 %)
(As of 10/19/2020 04:35 PM ET)
Today's Range
Now: GBX 476
50-Day Range
MA: GBX 500.98
52-Week Range
Now: GBX 476
Volume20,132 shs
Average Volume84,254 shs
Market Capitalization£3.38 billion
P/E RatioN/A
Dividend YieldN/A
Hutchison China MediTech Limited, a commercial-stage biopharmaceutical company, engages in discovery, development, and commercialization of targeted therapeutics and immunotherapies for cancer and immunological diseases in the People's Republic of China and Hong Kong. It operates through Innovation Platform and Commercial Platform segments. The company provides research and development services; and develops, manufactures, distributes, markets, and sells prescription and over-the-counter pharmaceutical products, and consumer health products under the Bai Yun Shan and Shang Yao brands. Its clinical stage drugs include Savolitinib, a MET inhibitor for the treatment of non-small cell lung cancer, papillary renal cell carcinoma, colorectal cancer, gastric cancer, and prostate cancer; and Fruquintinib, a inhibitor for the treatment of colorectal cancer and solid tumors. The company is also developing Surufatinib, an inhibitor for the treatment of pancreatic neuroendocrine tumors and solid tumors; and HMPL-523 for the treatment of hematological cancer and immunological diseases; HMPL-689 for the treatment of hematological cancer; HMPL-453 for the treatment of solid tumors; and HMPL-306 for the treatment of hematological malignancies, gliomas, and solid tumors, as well as epitinib and theliatinib, an EGFR inhibitor to penetrate the blood-brain barrier. Hutchison China MediTech Limited was founded in 2000 and is headquartered in Central, Hong Kong.
Read More
Hutchison China MediTech logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.0Community Rank: 3.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.84 out of 5 stars

Industry, Sector and Symbol

Industry Drug Manufacturers - Major



Sales & Book Value

Annual Sales£209.46 million
Cash FlowGBX 40.90 per share
Book ValueGBX 49.80 per share



Market Cap£3.38 billion
Next Earnings DateN/A
OptionableNot Optionable
GBX 476
-10.00 (-2.06 %)
(As of 10/19/2020 04:35 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive HCM News and Ratings via Email

Sign-up to receive the latest news and ratings for HCM and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Hutchison China MediTech (LON:HCM) Frequently Asked Questions

How has Hutchison China MediTech's stock price been impacted by COVID-19?

Hutchison China MediTech's stock was trading at GBX 348 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, HCM shares have increased by 36.8% and is now trading at GBX 476.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Hutchison China MediTech?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hutchison China MediTech in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Hutchison China MediTech

What price target have analysts set for HCM?

2 Wall Street analysts have issued twelve-month price targets for Hutchison China MediTech's stock. Their forecasts range from GBX 360 to GBX 360. On average, they anticipate Hutchison China MediTech's share price to reach GBX 360 in the next twelve months. This suggests that the stock has a possible downside of 24.4%.
View analysts' price targets for Hutchison China MediTech

Who are some of Hutchison China MediTech's key competitors?

What other stocks do shareholders of Hutchison China MediTech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Hutchison China MediTech investors own include Intelsat (I), Associated British Foods plc (ABF.L) (ABF), Fossil Group (FOSL), Chaarat Gold (CGH), AMC Entertainment (AMC), Bank of America (BAC), First Data (FDC), Air Canada (AC), Apollo Global Management (APO) and China Unicom (Hong Kong) (CHU).

Who are Hutchison China MediTech's key executives?

Hutchison China MediTech's management team includes the following people:
  • Mr. Chi Keung To B.Sc., M.B.A., BSc, ACGI, MBA, Exec. Chairman (Age 68, Pay $80k)
  • Mr. Christian Hogg B.Sc., M.B.A., BSc, MBA, CEO & Exec. Director (Age 54, Pay $1.44M)
  • Mr. Johnny Cheng C.A., BEc, CA, CFO & Exec. Director (Age 53, Pay $769.68k)
  • Dr. Wei-Guo Su B.Sc., Ph.D., Chief Scientific Officer, Exec. VP & Exec. Director (Age 63, Pay $1.13M)
  • Ms. Edith Shih B.S., M.A., BSE, MA, EdM, Solicitor, FCIS, FCS(PE), Company Sec. & Non-Exec. Director (Age 68, Pay $70k)

What is Hutchison China MediTech's stock symbol?

Hutchison China MediTech trades on the London Stock Exchange (LON) under the ticker symbol "HCM."

How do I buy shares of Hutchison China MediTech?

Shares of HCM and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Hutchison China MediTech's stock price today?

One share of HCM stock can currently be purchased for approximately GBX 476.

How big of a company is Hutchison China MediTech?

Hutchison China MediTech has a market capitalization of £3.38 billion and generates £209.46 million in revenue each year. Hutchison China MediTech employs 853 workers across the globe.

What is Hutchison China MediTech's official website?

The official website for Hutchison China MediTech is www.chi-med.com.

How can I contact Hutchison China MediTech?

The company can be reached via phone at +85221213888.

This page was last updated on 10/20/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.